Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Celgene To Acquire Gloucester | Contract Pharma

What are you searching for?

Sign in
Breaking News

Celgene To Acquire Gloucester

Celgene Corporation will acquire Gloucester Pharmaceuticals for $340 million in cash and as much as $300 million in milestone payments.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Celgene Corporation will acquire privately held Gloucester Pharmaceuticals for $340 million in cash and as much as $300 million in milestone payments. The acquisition is intended to strengthen Celgene’s position in the development of disease-altering therapies through innovative approaches for patients with rare and debilitating blood cancers. Gloucester develops new therapies that address the unmet medical needs in the treatment of cancer, including cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL) and other hematological malignancies.

“We are thrilled with this transaction because Celgene’s global leadership in the development and commercialization of innovative treatments for hematologic diseases makes them ideally suited to bring the clinical benefits of Istodax to patients with CTCL,” said Alan Colowick, M.D., chief executive officer of Gloucester.

Istodax was approved in November 2009 by the FDA for the treatment of CTCL in patients who have received at least one prior systemic therapy. Istodax has also received both orphan drug designation for the treatment of non-Hodgkin’s T-cell lymphomas, which includes CTCL and PTCL, and Fast Track status in PTCL from the FDA. The EMEA has granted it orphan status designation for the treatment of both CTCL and PTCL.

“This acquisition reflects our ongoing commitment to improving the lives of patients worldwide through innovative medicines discovered and developed both in-house and through external opportunities,” said Sol J. Barer, Ph.D., chairman and chief executive officer of Celgene. “We also would like to recognize the dedication, effort and leadership that Alan and his team have demonstrated in the process of developing and delivering Istodax to patients living with CTCL.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters